(A top pick Aug 22/03. Up 9.5%.) Still likes at this price. Investors will start looking at this in the last half of 2004 because the company will start reaping the benefits in 2005. Good dividend.
With the improvements that had taken place, there will have been a $5/6 stock-price taken out of the equation. Risk level has dropped even though the price is up.
With the improvements that had taken place, there will have been a $5/6 stock-price taken out of the equation. Risk level has dropped even though the price is up.
One of the few tech stocks that continues to trade at a reasonable multiple. They are in the process of acquiring Concorde EFS and will have to divest some operations sold in the near term, there will be some hiccups.
One of the few tech stocks that continues to trade at a reasonable multiple. They are in the process of acquiring Concorde EFS and will have to divest some operations sold in the near term, there will be some hiccups.
(A top pick Aug 22/03. Up 9.5%.) Still likes at this price. Investors will start looking at this in the last half of 2004 because the company will start reaping the benefits in 2005. Good dividend.
(A top pick Aug 22/03. Up 9.5%.) Still likes at this price. Investors will start looking at this in the last half of 2004 because the company will start reaping the benefits in 2005. Good dividend.
Have a very good pipeline. Faces significant generic exposure for the next few years because of patent exposure. On his focus list and will probably stay there for some time.
Have a very good pipeline. Faces significant generic exposure for the next few years because of patent exposure. On his focus list and will probably stay there for some time.
Doesn't have the potential high growth of some other tech names.For a long-term perspective can grow the top line 8/9% and can still generate bottom-line growth in the mid teens range. Incredible balance sheet.
Doesn't have the potential high growth of some other tech names.For a long-term perspective can grow the top line 8/9% and can still generate bottom-line growth in the mid teens range. Incredible balance sheet.
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.The strongest of the drug companies and the deepest pipeline.A good price to buy out for the long-term.
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.The strongest of the drug companies and the deepest pipeline.A good price to buy out for the long-term.
Long-term outlook does not appear to be very good.Their costs are very high compared to similar companies because their work is done in-house.A lot of competition.Strong balance sheet.
Long-term outlook does not appear to be very good.Their costs are very high compared to similar companies because their work is done in-house.A lot of competition.Strong balance sheet.
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.A good price to buy out for the long-term.
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.A good price to buy out for the long-term.
No longer a high flier.Acquisitions used to fuel their growth.No longer have the balance sheet to make acquisitions.Will have decent growth, but nothing exciting.Not cheap.
No longer a high flier.Acquisitions used to fuel their growth.No longer have the balance sheet to make acquisitions.Will have decent growth, but nothing exciting.Not cheap.
Has turned into a momentum play.September 23 is going to be a big day when they will debut their 64-bit chip.An interesting bet but still a lot of"show me".Cheap on a price to sales basis.Put a tight stop loss on it.
Has turned into a momentum play.September 23 is going to be a big day when they will debut their 64-bit chip.An interesting bet but still a lot of"show me".Cheap on a price to sales basis.Put a tight stop loss on it.
Generates tremendous amounts of free cash flow, which bodes well for the dividend story.Focused on paying down debt.4% dividend.Wireless is producing top and bottom-line growth.
Generates tremendous amounts of free cash flow, which bodes well for the dividend story.Focused on paying down debt.4% dividend.Wireless is producing top and bottom-line growth.
Investors had concerns on its lack of economic exposure and lower mortgage revenues compared to its peers.Earnings will probably come in better than expected.Buy for the 4% yield, earnings quality and growth.A good defensive stock.
Investors had concerns on its lack of economic exposure and lower mortgage revenues compared to its peers.Earnings will probably come in better than expected.Buy for the 4% yield, earnings quality and growth.A good defensive stock.
Has been a laggard.Attractive valuation.Good exposure to an economic recovery in the latter half of the year.The power outage could be a wild card as they sell massive power generators.Under $30 is a good price.
Has been a laggard.Attractive valuation.Good exposure to an economic recovery in the latter half of the year.The power outage could be a wild card as they sell massive power generators.Under $30 is a good price.
Has had a tough year.The price war with McDonald's has now ended.Introducing new menus.Their Tim Horton's franchise has performed well throughout.Good price.
Has had a tough year.The price war with McDonald's has now ended.Introducing new menus.Their Tim Horton's franchise has performed well throughout.Good price.